Literature DB >> 29308299

Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.

Stefanie Maurer1, Korbinian Nepomuk Kropp1, Gerd Klein2, Alexander Steinle3, Sebastian P Haen2, Juliane S Walz2, Clemens Hinterleitner2, Melanie Märklin1, Hans-Georg Kopp2, Helmut Rainer Salih1.   

Abstract

Platelets promote metastasis, among others by coating cancer cells traveling through the blood, which results in protection from NK cell immune-surveillance. The underlying mechanisms, however, remain to be fully elucidated. Here we report that platelet-coating reduces surface expression of NKG2D ligands, in particular MICA and MICB, on tumor cells, which was mirrored by enhanced release of their soluble ectodomains. Similar results were obtained upon exposure of tumor cells to platelet-releasate and can be attributed to the sheddases ADAM10 and ADAM17 that are detectable on the platelet surface and in releasate following activation and at higher levels on platelets of patients with metastasized lung cancer compared with healthy controls. Platelet-mediated NKG2DL-shedding in turn resulted in impaired "induced self" recognition by NK cells as revealed by diminished NKG2D-dependent lysis of tumor cells. Our results indicate that platelet-mediated NKG2DL-shedding may be involved in immune-evasion of (metastasizing) tumor cells from NK cell reactivity.

Entities:  

Keywords:  NK cells; cancer; immune-surveillance; metastasis; platelets

Year:  2017        PMID: 29308299      PMCID: PMC5749664          DOI: 10.1080/2162402X.2017.1364827

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  43 in total

1.  An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.

Authors:  S P Koerner; M C André; J S Leibold; P C Kousis; A Kübler; M Pal; S P Haen; H-J Bühring; L Grosse-Hovest; G Jung; H R Salih
Journal:  Leukemia       Date:  2016-07-20       Impact factor: 11.528

Review 2.  ADAMs: key components in EGFR signalling and development.

Authors:  Carl P Blobel
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

3.  Antimetastatic effects associated with platelet reduction.

Authors:  G J Gasic; T B Gasic; C C Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  1968-09       Impact factor: 11.205

Review 4.  Paraneoplastic thrombocytosis: the secrets of tumor self-promotion.

Authors:  Richard J Lin; Vahid Afshar-Kharghan; Andrew I Schafer
Journal:  Blood       Date:  2014-05-27       Impact factor: 22.113

Review 5.  Natural killer cell education and tolerance.

Authors:  Mark T Orr; Lewis L Lanier
Journal:  Cell       Date:  2010-09-17       Impact factor: 41.582

6.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

7.  Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.

Authors:  Philippe Boutet; Sonia Agüera-González; Susan Atkinson; Caroline J Pennington; Dylan R Edwards; Gillian Murphy; Hugh T Reyburn; Mar Valés-Gómez
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

8.  Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis.

Authors:  Eric Camerer; Aisha A Qazi; Daniel N Duong; Ivo Cornelissen; Rommel Advincula; Shaun R Coughlin
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

9.  RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry.

Authors:  Heiyoun Jung; Benjamin Hsiung; Kathleen Pestal; Emily Procyk; David H Raulet
Journal:  J Exp Med       Date:  2012-11-19       Impact factor: 14.307

Review 10.  New prospects on the NKG2D/NKG2DL system for oncology.

Authors:  Evelyn Ullrich; Joachim Koch; Adelheid Cerwenka; Alexander Steinle
Journal:  Oncoimmunology       Date:  2013-10-25       Impact factor: 8.110

View more
  23 in total

Review 1.  The Tumor Microenvironment Innately Modulates Cancer Progression.

Authors:  Dominique C Hinshaw; Lalita A Shevde
Journal:  Cancer Res       Date:  2019-07-26       Impact factor: 12.701

Review 2.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.

Authors:  Suchit Jhunjhunwala; Christian Hammer; Lélia Delamarre
Journal:  Nat Rev Cancer       Date:  2021-03-09       Impact factor: 60.716

3.  Functional visualization of NK cell-mediated killing of metastatic single tumor cells.

Authors:  Hiroshi Ichise; Shoko Tsukamoto; Tsuyoshi Hirashima; Yoshinobu Konishi; Choji Oki; Shinya Tsukiji; Satoshi Iwano; Atsushi Miyawaki; Kenta Sumiyama; Kenta Terai; Michiyuki Matsuda
Journal:  Elife       Date:  2022-02-03       Impact factor: 8.140

4.  Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells: Implications for the metastatic cascade.

Authors:  Christopher D Cluxton; Cathy Spillane; Sharon A O'Toole; Orla Sheils; Clair M Gardiner; John J O'Leary
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

5.  Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies.

Authors:  Martina Hinterleitner; Bence Sipos; Verena Wagner; Julia M Grottenthaler; Ulrich M Lauer; Lars Zender; Clemens Hinterleitner
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 6.  Exploring natural killer cell immunology as a therapeutic strategy in lung cancer.

Authors:  Jonas B Hess; Kate D Sutherland; Sarah A Best
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 7.  NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.

Authors:  Dominik Schmiedel; Ofer Mandelboim
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

8.  Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy.

Authors:  Jinyu Zhang; Pablo Saenz-Lopez Larrocha; Bin Zhang; Derek Wainwright; Payal Dhar; Jennifer D Wu
Journal:  J Immunother Cancer       Date:  2019-08-26       Impact factor: 13.751

Review 9.  NKG2D Ligand Shedding in Response to Stress: Role of ADAM10.

Authors:  Alessandra Zingoni; Elisabetta Vulpis; Luisa Loconte; Angela Santoni
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

Review 10.  Modulation of Immune Responses by Platelet-Derived ADAM10.

Authors:  Stefanie Maurer; Hans-Georg Kopp; Helmut R Salih; Korbinian N Kropp
Journal:  Front Immunol       Date:  2020-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.